Novo's Clayton facility makes semaglutide, the active ingredient in Wegovy and diabetes drug Ozempic. It also does manufacturing steps including filling, finishing and packaging the injections. It ...

A federal appeals court on Monday rejected Novo Nordisk's challenge to the U.S. government’s program that gives its Medicare health insurance plan the power to negotiate lower drug prices, the latest ...

Novo Nordisk is one of Europe’s largest companies and a global leader in the treatment of two major lifestyle diseases – diabetes and obesity. Read more here.

Novo Nordisk is well-positioned in the obesity drug market, with strong financials and anticipation for its oral Wegovy pill. See why NVO stock is a Buy now.

Novo Nordisk (NYSE:NVO) shares have moved little in recent sessions, with investors taking a wait-and-see approach. Market participants are weighing the company's recent performance metrics against ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

“[T]he Third Circuit found that CMS’ treatment of six [Novo Nordisk] products as a single drug was ultimately precluded by the IRA’s bar against judicial review.” Yesterday, the U.S. Court of Appeals ...

The Danish drugmaker plans to cut 9,000 jobs or 11% of its workforce, which would save it 8 billion Danish krone ($1.25 billion) annually.

Vltava Fund, an investment management company, recently released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Novo Nordisk, the Danish pharmaceutical giant behind Wegovy and Ozempic, has laid off dozens of employees at its largest U.S. manufacturing facility in Clayton, North Carolina. A Reuters analysis of ...